List of monoclonal antibodies

Jump to: navigation, search

This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies").

Name Target Source
Abagovomab go(v) o
Abciximab ci(r) xi
Adalimumab li(m) u
Adecatumumab tu(m) u
Afelimomab li(m) o
Alemtuzumab tu(m) zu
Altumomab tu(m) o
Ananeuzumab neu(r) zu
Anatumomab mafenatox tu(m) o
Anergrozumab ? zu
Anetumumab tu(m) u
Anrulizumab li(m) zu
Apolizumab li(m) zu
Arcitumomab tu(m) o
Aselizumab li(m) zu
Atlizumab li(m) zu
Atorolimumab li(m) u
Azulizumab li(m) zu
Balizumab li(m) zu
Bapineuzumab neu(r) zu
Basiliximab li(m) xi
Bavituximab tu(m) xi
Bectumomab tu(m) o
Belimumab li(m) u
Belizumab li(m) zu
Bertilimumab li(m) u
Besilesomab le(s) o
Betumumab tu(m) u
Bevacizumab ci(r) zu
Biciromab brallobarbital ci(r) o
Bivatuzumab mertansine tu(m) zu
Campath - Redirects to alemtuzumab tu(m) zu
Canakinumab ki(n) u
Cantuzumab mertansine tu(m) zu
Capromab pr(o) o
Catumaxomab tu(m) axo
Cedelizumab li(m) zu
Certolizumab pegol li(m) zu
Cetforlimumab li(m) u
Cetinlimumab li(m) u
Cetlalimumab li(m) u
Cetolimumab li(m) u
Cetuximab tu(m) xi
Cidfusituzumab tu(m) zu
Cidtuzumab tu(m) zu
Citilimumab li(m) u
Clenoliximab li(m) xi
Cynosumab o(s) u
Cynotumumab - Redirects to cynosumab o(s) u
Dacetuzumab tu(m) zu
Dacliximab - Redirects to daclizumab li(m) zu
Daclizumab li(m) zu
Denosumab o(s) u
Denotumumab - Redirects to denosumab o(s) u
Destilimumab li(m) u
Detumomab tu(m) o
Doraglizumab li(m) zu
Dorlimomab aritox li(m) o
Dorlixizumab li(m) xizu
Dorlizumab li(m) zu
Drinalizumab li(m) zu
Duntumumab tu(m) u
Durimulumab mu(l) u
Durlizumab li(m) zu
Durmulumab mu(l) u
Ecromeximab me(l) xi
Eculizumab li(m) zu
Edobacomab ba(c) o
Edrecolomab co(l) o
Efalizumab li(m) zu
Efungumab fu(ng) u
Elsilimomab li(m) o
Enlimomab pegol li(m) o
Enlimomab li(m) o
Epitumomab cituxetan tu(m) o
Epitumomab tu(m) o
Epkizumab ki(n) zu
Epratuzumab tu(m) zu
Erlizumab li(m) zu
Ertumaxomab tu(m) axo
Etaracizumab ci(r) zu
Etaratuzumab tu(m) zu
Exbivirumab vi(r) u
Extumumab tu(m) u
Efalizumab li(m) zu
Fanolesomab le(s) o
Faralimomab li(m) o
Felvizumab vi(r) zu
Fontolizumab li(m) zu
Futumumab tu(m) u
Galiximab li(m) xi
Gantenerumab ? u
Gavilimomab li(m) o
Gemtuzumab ozogamicin tu(m) zu
Genosumab o(s) u
Golimumab li(m) u
Gomiliximab li(m) xi
Hylizumab li(m) zu
Ibalizumab li(m) zu
Ibritumomab tiuxetan tu(m) o
Igovomab go(v) o
Imciromab ci(r) o
Infliximab li(m) xi
Inolimomab li(m) o
Inotuzumab ozogamicin tu(m) zu
Intumumab tu(m) u
Ipilimumab li(m) u
Iratumumab tu(m) u
Keliximab li(m) xi
Labetuzumab tu(m) zu
Lemalesomab le(s) o
Lebrilizumab li(m) zu
Lerdelimumab li(m) u
Lexatumumab tu(m) u
Lexitumumab tu(m) u
Libivirumab vi(r) u
Lintuzumab tu(m) zu
Lucalizumab li(m) zu
Lucatumumab tu(m) u
Lumiliximab li(m) xi
Mapatumumab tu(m) u
Maslimomab li(m) o
Matenazumab ? zu
Matuzumab tu(m) zu
Mepolizumab li(m) zu
Metelimumab li(m) u
Minretumomab tu(m) o
Mitumomab tu(m) o
Morolimumab li(m) u
Motavizumab vi(r) zu
Muromonab-CD3 monoclonal antibody ? o
Nacolomab tafenatox co(l) o
Naptumomab estafenatox tu(m) o
Natalizumab li(m) zu
Nebacumab ba(c) u
Nerelimomab li(m) o
Nimotuzumab tu(m) zu
Nofetumomab merpentan tu(m) o
Nolovizumab vi(r) zu
Numavizumab vi(r) zu
Ocrelizumab li(m) zu
Odulimomab li(m) o
Ofatumumab tu(m) u
Omalizumab li(m) zu
Oregovomab go(v) o
Oteliximab li(m) xi
Otelixizumab li(m) xizu
Pagibaximab ba(c) xi
Palivizumab vi(r) zu
Panitumumab tu(m) u
Pascolizumab li(m) zu
Pecfusituzumab tu(m) zu
Pectuzumab tu(m) zu
Pemtumomab tu(m) o
Pertuzumab tu(m) zu
Pexelizumab li(m) zu
Pintumomab tu(m) o
Priliximab li(m) xi
Pritumumab tu(m) u
Quartuzumab tu(m) zu
Quetumumab tu(m) u
Ralivizumab vi(r) zu
Ranibizumab ? zu
Raxibacumab ba(c) u
Regavirumab vi(r) u
Resatumumab tu(m) u
Restumumab tu(m) u
Reslivizumab vi(r) zu
Reslizumab li(m) zu
Resyvizumab vi(r) zu
Rilotumumab tu(m) u
Rituximab tu(m) xi
Rosutumumab tu(m) u
Rovelizumab li(m) zu
Ruplizumab li(m) zu
Satumomab tu(m) o
Sevirumab vi(r) u
Sibrotuzumab tu(m) zu
Siplizumab li(m) zu
Sontuzumab tu(m) zu
Stamulumab mu(l) u
Sulesomab le(s) o
Synosumab o(s) u
Tacatuzumab tetraxetan tu(m) zu
Tadocizumab ci(r) zu
Talineuzumab neu(r) zu
Talizumab li(m) zu
Taneuzumab neu(r) zu
Tanirazumab ? zu
Taplitumomab paptox tu(m) o
Tefibazumab ba(c) zu
Teglizumab li(m) zu
Telimomab aritox li(m) o
Teneliximab li(m) xi
Teplizumab li(m) zu
Ticilimumab - Redirects to tremelimumab li(m) u
Tiratumumab tu(m) u
Tocilizumab li(m) zu
Tolizumab li(m) zu
Toralizumab li(m) zu
Tositumomab tu(m) o
Tralizumab li(m) zu
Trastuzumab tu(m) zu
Treglizumab li(m) zu
Trelizumab li(m) zu
Tremelimumab li(m) u
Trilizumab li(m) zu
Tritumumab tu(m) u
Trixatumumab tu(m) u
Tucotuzumab celmoleukin tu(m) zu
Tucusituzumab tu(m) zu
Tuvirumab vi(r) u
Ubrelizumab li(m) zu
Umavizumab vi(r) zu
Urtoxazumab tox(a) zu
Valtumumab tu(m) u
Vapaliximab li(m) xi
Vepalimomab li(m) o
Vexatumumab tu(m) u
Visilizumab li(m) zu
Volociximab ci(r) xi
Votumumab tu(m) u
Xalizumab li(m) zu
Zalutumumab tu(m) u
Zanolimumab li(m) u
Ziralimumab li(m) u
Zolimomab aritox li(m) o
Zulizumab li(m) zu

Linked-in.jpg